Honda et al. demonstrated improvements in obesity, dyslipidemia, and histological markers of NAFLD in two rodent models of NASH using permafibrate treatment, with increased hepatic expression of acyl-CoA oxidase 1 (ACOX1) and uncoupling protein 3 (UCP3) [113]. This evidence concerns the gene UCP3 and metabolic dysfunction-associated steatohepatitis.